Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk.
Adult
Age Factors
Aged
Analgesics
/ classification
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Carcinoma, Ovarian Epithelial
/ epidemiology
Case-Control Studies
Contraceptives, Oral
/ therapeutic use
Dysmenorrhea
/ drug therapy
Female
History, 20th Century
History, 21st Century
Humans
Middle Aged
New England
/ epidemiology
Ovarian Neoplasms
/ epidemiology
Parity
/ physiology
Pregnancy
Registries
Risk Factors
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
04
03
2021
revised:
15
04
2021
accepted:
18
05
2021
pubmed:
11
7
2021
medline:
25
3
2022
entrez:
10
7
2021
Statut:
ppublish
Résumé
Menstrual pain has been associated with increased ovarian cancer risk, presumably through increased inflammation, which is known to play a critical role in ovarian carcinogenesis. Analgesic medications are frequently used to treat menstrual pain, some of which lower ovarian cancer risk. In this study, we examined the association between analgesic use for menstrual pain during the premenopausal period and ovarian cancer risk among women with history of menstrual pain. We used data from the New England Case-Control Study, including 1,187 epithelial ovarian cancer cases and 1,225 population-based controls enrolled between 1998 and 2008 with detailed information on analgesic use for their menstrual pain. We used unconditional logistic regression to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for the association between analgesic use (i.e., aspirin, ibuprofen, acetaminophen) for menstrual pain and ovarian cancer risk. We further conducted a stratified analysis by intensity of menstrual pain (mild/moderate, severe). Among women with menstrual pain during their 20s and 30s, ever use of analgesics for menstrual pain was not significantly associated with ovarian cancer risk. However, among women with severe menstrual pain, ever use of aspirin or acetaminophen for menstrual pain was inversely associated with risk (OR, 0.41; 95% CI, 0.18-0.94 and OR, 0.43; 95% CI, 0.21-0.88 compared with never users, respectively). No significant association was observed between analgesic use and ovarian cancer risk among women with mild/moderate menstrual pain (
Identifiants
pubmed: 34244153
pii: 1940-6207.CAPR-21-0090
doi: 10.1158/1940-6207.CAPR-21-0090
pmc: PMC8344407
mid: NIHMS1724305
doi:
Substances chimiques
Analgesics
0
Anti-Inflammatory Agents, Non-Steroidal
0
Contraceptives, Oral
0
Types de publication
Historical Article
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
795-802Subventions
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA054419
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67
pubmed: 10469746
Cancer Causes Control. 2014 Dec;25(12):1725-31
pubmed: 25189423
Clin Infect Dis. 2000 Oct;31 Suppl 5:S202-10
pubmed: 11113024
Cancer Res. 2020 Mar 1;80(5):1210-1218
pubmed: 31932455
Cancer Res. 2019 Oct 15;79(20):5442-5451
pubmed: 31462430
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
Gynecol Oncol. 1979 Jun;7(3):325-44
pubmed: 447120
Mol Cell Endocrinol. 2006 Jun 27;252(1-2):191-200
pubmed: 16701939
Mol Cancer. 2006 Nov 16;5:62
pubmed: 17107625
Am J Epidemiol. 2003 Oct 1;158(7):629-38
pubmed: 14507598
Int J Cancer. 2018 Feb 1;142(3):460-469
pubmed: 28833087
Reprod Biol Endocrinol. 2010 Aug 16;8:98
pubmed: 20712898
Lancet Oncol. 2012 Apr;13(4):385-94
pubmed: 22361336
Gynecol Oncol. 2004 Feb;92(2):622-7
pubmed: 14766256
Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11
pubmed: 15963707
J Natl Cancer Inst. 2019 Feb 1;111(2):137-145
pubmed: 29860330
Int J Epidemiol. 1992 Feb;21(1):23-9
pubmed: 1544753
Br J Cancer. 2001 Mar 2;84(5):714-21
pubmed: 11237375
J Natl Cancer Inst. 2014 Feb;106(2):djt431
pubmed: 24503200
Epidemiology. 2000 Mar;11(2):111-7
pubmed: 11021606
Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):687-93
pubmed: 12512245
Thromb Res. 2003 Jun 15;110(5-6):255-8
pubmed: 14592543
Cancer Causes Control. 2017 May;28(5):405-414
pubmed: 28251458
Endocr Relat Cancer. 2014 Aug;21(4):533-43
pubmed: 24969217
Gynecol Oncol. 2013 Jun;129(3):613-9
pubmed: 23422504
Innate Immun. 2015 Aug;21(6):587-97
pubmed: 25575547
Int J Environ Res Public Health. 2020 Feb 13;17(4):
pubmed: 32069859
Cancers (Basel). 2018 Jul 30;10(8):
pubmed: 30061485
Obstet Gynecol. 2011 May;117(5):1042-1050
pubmed: 21471855
Am J Epidemiol. 2013 Oct 15;178(8):1256-64
pubmed: 23966559
Endocr Rev. 2019 Apr 1;40(2):369-416
pubmed: 30496379
Gynecol Oncol. 2004 Mar;92(3):806-12
pubmed: 14984945
Curr Pharm Des. 2004;10(6):577-88
pubmed: 14965321
Am J Epidemiol. 2017 Jan 1;185(1):8-20
pubmed: 27941069
Am J Pathol. 2002 Mar;160(3):893-903
pubmed: 11891188
Gynecol Oncol. 2014 Nov;135(2):297-304
pubmed: 25158036
Int J Cancer. 2008 Jan 1;122(1):170-6
pubmed: 17721999
Endocrinology. 2006 May;147(5):2338-45
pubmed: 16484319
Biol Reprod. 2019 Nov 21;101(5):961-974
pubmed: 31347667